Avadel Pharmaceuticals Welcomes Kevin Springman as VP of Sales

Avadel Pharmaceuticals has named Kevin Springman as its new Vice President of Sales, bringing over 25 years of industry expertise to the role. Known for his leadership in rare disease drug launches and commercial strategy, Springman’s appointment comes at a crucial time as Avadel expands the market presence of LUMRYZ™, its FDA-approved narcolepsy treatment. CEO Greg Divis praised Springman’s proven ability to build and lead specialized sales teams, emphasizing his role in unlocking LUMRYZ’s billion-dollar potential.

Springman, who has held executive positions at AstraZeneca, Sobi, and Albireo Pharma, expressed excitement about shaping Avadel’s commercial success. He aims to optimize sales strategies and ensure LUMRYZ reaches more patients in need of improved sleep disorder treatments. With ongoing advancements, including a Phase 3 trial in idiopathic hypersomnia (IH), Avadel is poised to lead the sleep medicine space, and Springman’s expertise will be key to that growth.